Premium
A prospective audit of the adherence to a new magnesium sulphate guideline for the neuroprotection of infants born less than 30 weeks' gestation
Author(s) -
Tan Yu Hwee,
Groom Katie M.
Publication year - 2015
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/ajo.12271
Subject(s) - medicine , guideline , gestation , cerebral palsy , prospective cohort study , audit , obstetrics , pregnancy , pediatrics , surgery , physical therapy , management , pathology , biology , economics , genetics
Antenatal magnesium sulphate reduces the risk of cerebral palsy in babies born <30 weeks’ gestation. A guideline for its use in women at imminent risk of preterm birth was implemented at N ational W omen's H ealth, A uckland C ity H ospital in 2012. This prospective audit assessed adherence to the guideline in women delivering at <30 weeks in the first year after its implementation. Magnesium sulphate was safely administered to 58 of 71 (82%) eligible women and 58 of 61 (95%) of women where it was clinically appropriate and practically achievable.